JAK1 inhibitor overview
In development for alopecia areata, chronic hand eczema, and vitiligo.
Details
The active ingredient in ARQ-252 and ARQ-255 is a selective and highly potent* topical janus kinase 1 (JAK1) inhibitor.1
- The JAK1 inhibitor in ARQ-252 and ARQ-255 demonstrates greater potency for JAK1 than JAK2
- ARQ-252 is a cream formulation being investigated for the treatment of chronic hand eczema and vitiligo
- ARQ-255 is formulated as a suspension, designed to deliver the drug deep into the dermis, and will be investigated as a treatment for alopecia areata
*In vitro data. Clinical efficacy claims cannot be made.
Role of JAK1 in immunomodulation
JAK-dependent cytokines contribute to immunodermatologic conditions.2,3
Selective JAK1 inhibition modulates cutaneous immunology pathways
Selective JAK1 inhibition modulates or reduces the activity of specific cytokines while maintaining other JAK-dependent immunomodulatory pathways.2
IFN = interferon, IL = interleukin, JAK = janus kinase, Tyk = tyrosine kinase.
Therapy
ARQ-252 and ARQ-255 are the same investigational JAK1 inhibitor; ARQ-252 is under investigation as a topical cream and ARQ-255 as a suspension.
*In vitro data. Clinical efficacy claims cannot be made.
References
1. Data on File. Arcutis Biotherapeutics, Inc. 2. Schwartz et al. Nat Rev Drug Discov. 2017;17:78. 3. Fragoulis et al. Rheumatology (Oxford). 2019;58:i43-i54.